DailyIQ
Last updated11 minutes ago

KYMR·Kymera Therapeutics Inc.

$106.74
-5.34 (-4.76%)
Overnight$106.68-0.06 (-0.06%)
High
$112.06
Open
$110.83
Market Cap
8.96B
52W High
$131.05
Low
$106.52
P. Close
$106.74
P/E
-
52W Low
$55.26
Fwd P/E
-20.93
DailyIQ Est.
$146.94
Inst. Ownership
43.5%
Short Interest
11.80%
Days to Cover
12.0
Technical Score (1D)
36
BEARISH
News Sentiment
63
BULLISH
The 1D score for Kymera Therapeutics Inc. (KYMR) is 36, with a SELL lean and weakening momentum. The price structure is compressed and neither trend indicators nor sentiment are offering a strong directional read right now. Sentiment at 63 is diverging from the flat technical backdrop - the two are essentially in sync, but both are pointing to indecision rather than conviction. Trying to get ahead of the direction in conditions like this tends to produce more frustration than results. Traders should watch for a breakout from the $107.90 to $116.90 range, treating either extreme as a potential trigger. Patience at this stage typically outperforms forcing a trade. Range-bound conditions like this reward fading the extremes more than committing to a direction - selling strength near $116.90 and covering near $107.90, rather than betting on which way the eventual break goes. That approach stops working the moment volume expands on a close outside the range, which is the signal to abandon the range-trade and respect the new direction.
LOW TARGET
$111 +4.0%
2 analysts
MEAN TARGET
$139 +30.6%
10 analysts
HIGH TARGET
$180 +68.7%
20 analysts
PRICE RANGE
$111.00 - $180.00
SB / B / H / S / SS
10/16/4/1/1
DAILYIQ EST.
$146.94 (+37.7%)
Bought (1Y)
0 shares
$0
Sold (1Y)
3,638,684 shares
$391.4M
Mainolfi NelloChief Executive Officer
Option Exercise30,000 shares2026-10-01
Mainolfi NelloChief Executive Officer
Sell262 shares2026-10-01
Mainolfi NelloChief Executive Officer
Sell8,230 shares2026-10-01
Mainolfi NelloChief Executive Officer
Sell7,601 shares2026-10-01
Mainolfi NelloChief Executive Officer
Sell4,876 shares2026-10-01
32/ 100
Bearish
Overall: Bearish
✕Revenue declining year over year
✕Negative net margin
✕Negative operating cash flow
Net Margin
-794.0%
Revenue CAGR
54.0%
Current Ratio
10.47x
Return on Equity
-19.7%

EPS

EstBeatMiss
$-1.34$-1.18$-1.02$-0.87$-0.71Q3'25Q3'26
QtrEstActual+/−
Q3'26$-1.27 - -
Q3'25$-0.78$-0.94-20.3%

Revenue

EstBeatMiss
$3M$3M$3M$3M$3MQ3'25Q3'26
QtrEstActual+/−
Q3'26$3M - -
Q3'25 - $3M -

Market Data

KYMR Stock Snapshot

NEUTRAL36/100
$106.68−$0.06 (0.1%)
Market cap
8.96B
Day range
$106.52 – $112.06
News sentiment
63/100 · Bullish
Analyst target
$139.35 (+30.6%)
Consensus
Buy · 32 analysts
52-week range+93.1% off low · -18.6% from high
$55.26$131.05
Price $106.68 DailyIQ Est. $146.94

The setup on Kymera Therapeutics Inc. is patient: consolidation, not accumulation or distribution. Company-specific news dominates here; sector-level flows matter less than for larger names.

Behaviour On Record

What KYMR's own history says about today's numbers

Realized volatility (21d)
39.0% 8th pct
Below its peak
-12.9%
vs 200-day average
+20.1%
Up days (1y)
52%

Kymera Therapeutics Inc. is currently running 39.0% annualised volatility over the last 21 sessions. Measured against KYMR's own 6 years of daily returns rather than a market-wide average, that is the 8th percentile — unusually subdued by its own history, against a typical reading of 64.8%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

KYMR is trading -12.9% below its running peak. Across 5 full years on file, its median worst-drawdown-in-a-year was -63.6%, and the deepest was -78.7% in 2022. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.

Price sits +20.1% from its 200-day moving average. Against every other day in its history, that gap ranks at the 64th percentile — a somewhat wider gap than its own norm. Over the past year KYMR closed higher on 52% of sessions, and it is currently 3 sessions into a rising streak.

On October specifically: over 6 years of records, KYMR finished the month higher 3 of 6 times, with a median return of +6.1% and an average of +10.8%. Its strongest month historically has been November at +18.0% on average, its weakest May at -11.6%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: KYMR has opened more than 2% away from the prior close in 262 of 1,540 sessions (17.0% of the time), with the largest gaps running +23.0% and -12.1%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

All figures computed from 1,541 daily closes between 2020-08-21 and 2026-10-09, split-adjusted, recomputed daily. Percentiles are against KYMR's own 6-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of KYMR's sector?

Kymera Therapeutics Inc. sits in the Health Care sector, currently ranked 4th of 12 GICS sectors by relative-strength rotation score (improving). Within its narrower Biotechnology industry group, KYMR ranks 13th of 15 tracked industries, lagging.

Sector rank
#4 of 12
Sector state
Improving
Sector rotation score
73
Industry rank
#13 of 15

Options Market

What is the options market pricing for KYMR?

CallsPuts

For Kymera Therapeutics Inc.'s nearest expiry (2026-10-16, 2 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.64), with at-the-money implied volatility around 108.0%. The options market is pricing roughly a ±6.2% move by that expiry — a range of about $105.17–$118.99.

Put/call ratio (2026-10-16)
0.64
ATM implied volatility
108.0%
Total open interest
54
Expected move by 2026-10-16
±6.2% ($105.17–$118.99)

Analyst Rating Changes

Are analysts turning bullish or bearish on KYMR?

Raymond James most recently initiated coverage on Kymera Therapeutics Inc. to Outperform on Oct 9, 2026 with a price target of $140. Over the last 90 days, coverage has run 1 upgrade against 0 downgrades, a net bullish lean.

Latest action
Raymond James — Outperform
90-day upgrades
1
90-day downgrades
0
Net rating momentum
+1
DateFirmActionRatingPrice target
Oct 9, 2026Raymond JamesInitiatedOutperform$140
Oct 5, 2026CitigroupMaintainedBuy$135 → $150
Sep 22, 2026StifelMaintainedBuy$132 → $152
Sep 14, 2026B of A SecuritiesMaintainedBuy$123 → $144
Sep 10, 2026Wolfe ResearchUpgradePeer Perform → Outperform-
Aug 31, 2026GuggenheimMaintainedBuy$135 → $170
Aug 27, 2026Wells FargoMaintainedOverweight$116 → $151
Aug 6, 2026BarclaysMaintainedOverweight$133 → $139
Jul 30, 2026Deutsche BankInitiatedHold$120
Jul 28, 2026GuggenheimMaintainedBuy$125 → $135
Jul 16, 2026MizuhoMaintainedOutperform$120 → $140
Jul 13, 2026RBC CapitalDowngradeOutperform → Sector Perform$106 → $115

ETF holders

ETFs holding KYMR

News Sentiment Analysis

Sentiment gathered from recent headlines

63/100
Strong NegativeNeutralStrong Positive
MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Kymera Therapeutics announced that its STAT6 degrader KT‑621 will enter pivotal BROADEN2 Phase 2b trials for atopic dermatitis, positioning the program as a potential competitor to Dupixent. The company highlighted the drug’s unique mechanism and early preclinical promise, suggesting a possible upside if the data meet expectations. The announcement did not provide any results yet, so the impact remains speculative but indicates a positive development for Kymera’s pipeline.
What did this article say?
An analyst from American Express announced a new bullish coverage on Kymera (KYMR), issuing an Outperform rating. The analyst highlighted Kymera’s recent product launches and growing market share as key catalysts. The coverage upgrade follows a broader positive sentiment toward the company’s strategic positioning in the fintech sector. This move is expected to influence investor perception and could support the stock’s upward momentum.
What did this article say?
Raymond James analyst Thomas Deal announced coverage of Kymera Therapeutics (NASDAQ:KYMR) on October 9, assigning an Outperform rating. The firm set a price target of $140, signaling a bullish view on the company’s prospects. The coverage launch reflects confidence in Kymera’s pipeline and potential market traction. This upgrade is expected to influence investor sentiment and could lift the stock price.
What did this article say?
Citigroup analyst Geoff Meacham upgraded Kymera Therapeutics to a Buy rating and increased the price target from $135 to $150. The upgrade reflects confidence in the company’s pipeline and recent clinical progress. The higher target suggests a bullish outlook for the stock’s valuation. This move is expected to influence investor sentiment and trading activity. The rating change signals a positive market view of Kymera’s prospects.
What did this article say?
Stifel analyst Alex Thompson has upgraded Kymera Therapeutics to a Buy rating and increased the price target from $132 to $152. The upgrade reflects confidence in the company’s pipeline and recent clinical data. The higher target suggests a bullish outlook on Kymera’s growth prospects.
What did this article say?
Kymera Therapeutics (KYMR) presented at the Morgan Stanley 24th Annual Global Healthcare Conference, outlining recent progress in its oncology pipeline and upcoming clinical milestones. The company emphasized the status of its lead candidate in phase 2 trials, noting enrollment targets and projected timelines. Management reiterated its commitment to regulatory milestones and discussed potential partnership opportunities. No new financial guidance or material corporate actions were disclosed, suggesting a routine update rather than a catalyst.
What did this article say?
B of A Securities upgraded its view on Kymera Therapeutics, raising the price target from $123 to $144 while maintaining a Buy rating. The move reflects confidence in the company’s pipeline and recent clinical milestones. The upgrade signals a bullish outlook for investors, suggesting potential upside if the company continues to progress its drug development program.
What did this article say?
Bank of America upgraded Kymera Therapeutics’ price target from $123 to $144, reflecting a more optimistic view of the company’s prospects. The new target aligns with a buy rating and an average analyst consensus of $137.73. The upgrade signals confidence in Kymera’s pipeline and potential market positioning.
What did this article say?
Kymera Therapeutics (KYMR) participated in Citigroup’s Biopharma Back to School Summit on September 10, 2026, delivering a presentation on its ongoing research and development pipeline. The event served as a platform for the company to update investors and industry peers on progress, without announcing new financial guidance or regulatory milestones. The presentation was largely informational, reflecting routine engagement rather than a material corporate development.
What did this article say?
Wolfe Research upgraded Kymera Therapeutics from Peer Perform to Outperform, citing robust clinical data and a favorable pipeline outlook. The analyst highlighted recent positive trial results for the company’s lead oncology asset and noted an expanding commercial strategy. This upgrade signals renewed confidence in Kymera’s growth trajectory and may influence short‑term valuation expectations.

Technical Analysis

Real-time indicators across multiple timeframes

36
BEARISH
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $3.92B combined position · 17 adding, 7 trimming, 1 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
FMR LLC (Fidelity)▲ Buy12,349,25614.71%$1.42B2026-08-13
BlackRock, Inc.▲ Buy5,538,2106.60%$635.07M2026-08-07
Vanguard Group Inc▲ Buy6,267,6447.46%$487.69M2026-01-29
Wellington Management Group LLP▼ Sell3,675,0284.38%$421.42M2026-08-14
Geode Capital Management, LLC▲ Buy1,816,3312.16%$208.32M2026-08-12
Capital Research Global Investors▼ Sell1,388,8811.65%$159.26M2026-08-12
Goldman Sachs Group Inc▲ Buy1,187,3331.41%$136.15M2026-08-14
Norges Bank▲ Buy757,2460.90%$86.83M2026-08-12
AllianceBernstein L.P.▲ Buy981,5211.17%$81.75M2026-08-14
Northern Trust Corp▲ Buy581,9070.69%$66.73M2026-08-13
Bank of America Corp▲ Buy378,2860.45%$43.38M2026-08-14
Two Sigma Investments, LP▲ Buy371,3740.44%$42.59M2026-08-14
Adage Capital Partners GP, L.L.C.▼ Sell200,0000.24%$22.93M2026-08-14
Morgan Stanley▼ Sell194,8430.23%$22.34M2026-08-13
Marshall Wace, LLP▲ Buy167,5170.20%$19.21M2026-08-13
Citadel Advisors LLC▼ Sell111,5550.13%$12.79M2026-09-02
JPMorgan Chase & Co▼ Sell113,0620.13%$12.63M2026-08-12
Squarepoint Ops LLC▲ Buy97,1890.12%$11.14M2026-08-14
Citigroup Inc▲ Buy77,7840.09%$8.92M2026-08-03
Wells Fargo & Company▲ Buy72,1600.09%$8.27M2026-08-14
Invesco Ltd.▼ Sell60,8130.07%$6.97M2026-08-14
Prudential Financial Inc▲ Buy19,2900.02%$2.21M2026-08-12
Man Group plc▲ Buy19,0850.02%$2.19M2026-08-14
Janus Henderson Group plc• Hold21,0580.03%$1.75M2026-05-18
Fisher Asset Management, LLC▲ New12,7320.02%$1.46M2026-08-04
Q2 2026 flow:3.08M sh bought ($349.74M)720.9K sh sold ($82.63M)net +2.35M sh (+$267.11M)